Intelligence · Clinical Pipeline

Phase II Pipeline Programs

Proof-of-concept and dose-finding clinical programs in Phase II development.

Programs: 7,238

Quick answer

NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.

Top sponsors

Alnuctamab, Alnuctamab, CC-92480 0.3 mg, CC-92480 0.4 mg, CC-92480 0.6 mg, DEXAMETHASONE, CC-92480 0.2 mg

Celgene Europe Limited

Relapsed and/or Refractory Multiple Myeloma

phase 2 small molecule active

1 trial
AloCelyvir

The George Institute

mEtastatic Uveal Melanoma

phase 2 small molecule active

1 trial
Alogabat

Hoffmann-La Roche

Angelman Syndrome

phase 2 small molecule completed

1 trial
Alpelisib

United Therapeutics Europe Ltd

Breast Cancer

phase 2 small molecule completed

1 trial
Alphagan 2 mg/ml colirio en solución, Brimonidine Tartrate 0.2% w/v Eye Drops., Mirvetuximab Soravtansine, Pred Forte 10 mg/ml colirio en suspensión, Pred Forte 1% w/v, Eye Drops Suspension

AbbVie Deutschland GmbH & Co. KG

Recurrent Ovarian Cancer with High Folate Receptor-Alpha Expression

phase 2 small molecule active

1 trial
Alpharix suspensie voor injectie in een voorgevulde spuit Trivalent griepvaccin (gefragmenteerd virion, geïnactiveerd)

GlaxoSmithKline

Influenza, Human

phase 2 small molecule active

1 trial
Alpharix suspensie voor injectie in een voorgevulde spuit Trivalent griepvaccin (gefragmenteerd virion, geïnactiveerd)

GlaxoSmithKline

Influenza, Human

phase 2 small molecule active

1 trial
Alprazolam

BRIGHT MINDS BIOSCIENCES INC.

Drug Interactions

phase 2 small molecule active

1 trial
Alteplase

United Therapeutics Europe Ltd

Myocardial Infarction

phase 2 small molecule completed

1 trial
Alunbrig 30 mg film-coated tablets, CRIZOTINIB, LORLATINIB, Zykadia 150 mg hard capsules, ALECTINIB

The George Institute

locally advanced (stage III) and not suitable for curative treatment, or metastatic (stage IV) ALK+ NSCLC, ALK+ NSCLC

phase 2 small molecule active

1 trial
Alvelestat

Mereo BioPharma Group plc

Covid19

phase 2 small molecule completed

1 trial
Alvelestat (MPH966)

Mereo BioPharma Group plc

Alpha-1 Antitrypsin Deficiency (AATD)

phase 2 small molecule completed

1 trial
Alxn1920 placebo product, ALXN1920

Alexion Europe SAS

Primary Mebranous Nephropathy (PMN)

phase 2 small molecule active

1 trial
Amcenestrant

Sanofi Pasteur

Breast Cancer Metastatic

phase 2 small molecule terminated

1 trial
Ametinib combined with bevacizumab

The First People's Hospital of Lianyungang

Non-small Cell Lung Cancer

phase 2 small molecule active

1 trial
Amifampridine Phosphate

CATALYST PHARMACEUTICALS, INC.

Muscular Atrophy, Spinal

phase 2 small molecule completed

1 trial
Amifampridine Phosphate 10 MG Oral Tablet

CATALYST PHARMACEUTICALS, INC.

Spinal Muscular Atrophy Type 3

phase 2 small molecule terminated

1 trial
Amikacin (BAY41-6551)

Nektar Therapeutics UK Limited

Pneumonia

phase 2 small molecule completed

1 trial
Amikacin inhalation solution (BAY41-6551)

Nektar Therapeutics UK Limited

Pneumonia

phase 2 small molecule completed

1 trial
Amiloride

United Therapeutics Europe Ltd

Secondary Progressive Multiple Sclerosis

phase 2 small molecule completed

1 trial
Amimox 500 mg filmdragerade tabletter, Kåvepenin 800 mg filmdragerade tabletter

The George Institute

Need of Oral bone augmentation

phase 2 small molecule active

1 trial
Amlitelimab, Amlitelimab matching placebo comprised of the same excipients as the Test product without the active substance

Sanofi-aventis Healthcare Pty Ltd

Hidradenitis

phase 2 small molecule active

1 trial
Amlitelimab, Amlitelimab matching placebo to test product

Sanofi-aventis Healthcare Pty Ltd

Coeliac disease

phase 2 small molecule active

1 trial
Amlitelimab, Amlitelimab matching placebo to test product

Sanofi-aventis Healthcare Pty Ltd

Alopecia areata

phase 2 small molecule active

1 trial
Amlitelimab, Placebo

Sanofi-aventis Healthcare Pty Ltd

Asthma

phase 2 small molecule active

1 trial
Amondys 45

Sarepta Therapeutics

Duchenne Muscular Dystrophy

phase 2 small molecule completed

1 trial
Amphotericin B

Matinas BioPharma Holdings

Candidiasis, Chronic Mucocutaneous

phase 2 small molecule completed

1 trial
Amyvid 1900 MBq/mL solution for injection, Neuraceq 300 MBq/mL solution for injection, 0.9% (w/v) sodium chloride (Normal Saline), VIZAMYL 400 MBq/mL solution for injection, Amyvid 800 MBq/mL solution for injection

GlaxoSmithKline

Alzheimer's Disease

phase 2 small molecule active

1 trial
Amyvid 800 MBq/mL solution for injection, ACU193 matching Placebo, Neuraceq 300 MBq/mL solution for injection, ACU193, VIZAMYL 400 MBq/mL solution for injection

Acumen Pharmaceuticals

Early Alzheimer’s Disease (Mild Cognitive Impairment and Mild Dementia Due to Alzheimer’s Disease)

phase 2 small molecule active

1 trial
An Adaptive Dose Escalation and Expansion Basket Trial to Explore the Safety, Pharmacology, and Clinical Activity of TGD001 in Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP) and Other Thrombotic Microangiopathies

Lacuna Pharma Pty Ltd

Immune-Mediated Thrombotic Thrombocytopenic Purpura, Thrombotic microangiopathy

phase 2 other active

1 trial
An Open-Label, Multi-Center, Phase Ib/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin (Plus A Single Pretreatment Dose of Obinutuzumab) in Adult Patients with Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma

Hoffmann-La Roche

Relapsed/refractory (r/r) B-cell Non-Hodgkin’s Lymphoma (NHL)

phase 2 other active

1 trial
An Open-label, Multicenter, Phase 2 Dose Optimization and Expansion Study to Evaluate the Safety and Efficacy of BB-1701, an anti-human epidermal growth factor receptor 2 (anti-HER2) antibody-drug conjugate (ADC), in Previously Treated Subjects with HER2-positive or HER2-low Unresectable or Metastatic Breast Cancer

Eisai Co.,

HER2 positive or HER2-low metastatic breast cancer

phase 2 other active

1 trial
An Open-label, Phase I/II First-in-Human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumor Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants with Advanced Solid Tumors

Ipsen

Pancreatic Ductal Adenocarcinoma, Melanoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Solid tumors

phase 2 other active

1 trial
An Open-label, Single-arm, Multicenter Pilot Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Pegcetacoplan in Patients with Transplant-associated Thrombotic Microangiopathy (TA-TMA) After Hematopoietic Stem Cell Transplantation (HSCT)

Swedish Orphan Biovitrum AB (publ)

Transplant-associated Thrombotic Microangiopathy (TA TMA)

phase 2 other active

1 trial
An open label extension study to evaluate the long-term safety and efficacy of subcutaneous lunsekimig in adult participants with asthma who participated in study DRI16762 or ACT18301

Sanofi-aventis Healthcare Pty Ltd

Asthma

phase 2 other active

1 trial
An open-label, dose-escalation, dose-finding, and proof-of-concept trial of SP-420 in subjects with transfusion-dependent α- or β-thalassemia or low-risk myelodysplastic syndromes

Lacuna Pharma Pty Ltd

transfusion-dependent α- or β-thalassemia or low-risk myelodysplastic syndromes

phase 2 other active

1 trial
An open-label, single-arm extension study to evaluate the long-term safety, tolerability, and efficacy of KL1333 (napazimone) in patients with primary mitochondrial disease

Pharming Technologies B.V.

Adult patients with primary mitochondrial disease

phase 2 other active

1 trial
Analogs, Prostaglandin E1

Vera Therapeutics

Covid19

phase 2 small molecule terminated

1 trial
Andecaliximab

Gilead Sciences Ireland UC

Crohn's Disease

phase 2 small molecule terminated

1 trial
Angiotensin (1-7)

United Therapeutics Europe Ltd

Traumatic Brain Injury

phase 2 small molecule active

1 trial
Anlotinib

The First People's Hospital of Lianyungang

Non-Small-Cell Lung Cancer

phase 2 small molecule active

1 trial
Anlotinib Hydrochloride

The First People's Hospital of Lianyungang

Effect of Drugs

phase 2 small molecule active

1 trial
Anlotinib and Sintilimab injection

The First People's Hospital of Lianyungang

Advanced Hepatocellular Carcinoma

phase 2 small molecule active

1 trial
Anlotinib combined Docetaxel

Xiyuan Hospital of China Academy of Chinese Medical Sciences

Non-small Cell Lung Cancer

phase 2 small molecule active

1 trial
Anlotinib plus Pemetrexed

Henan Provincial People's Hospital

Non-squamous Cell Non-Small Cell Lung Cancer

phase 2 small molecule active

1 trial
Anlotinib+ Liposomal Doxorubicin

The First People's Hospital of Lianyungang

Sarcoma

phase 2 small molecule active

1 trial
Anrotinib plus Tirelizumab

Xiyuan Hospital of China Academy of Chinese Medical Sciences

Nasopharyngeal Carcinoma

phase 2 small molecule active

1 trial
Anterior lamellar nanostructured artificial human cornea.

Lxo Ireland Designated Activity Company

Severe Trophic Corneal Ulcers Refractory to Conventional Treatment

phase 2 small molecule completed

1 trial

Frequently asked questions

How many Phase II pipeline programs are in the directory?

7,238 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Data attribution: Data sources · All pipeline programs

Quick answer

Top sponsors

Alnuctamab, Alnuctamab, CC-92480 0.3 mg, CC-92480 0.4 mg, CC-92480 0.6 mg, DEXAMETHASONE, CC-92480 0.2 mg

AloCelyvir

Alogabat

Alpelisib

Alphagan 2 mg/ml colirio en solución, Brimonidine Tartrate 0.2% w/v Eye Drops., Mirvetuximab Soravtansine, Pred Forte 10 mg/ml colirio en suspensión, Pred Forte 1% w/v, Eye Drops Suspension

Alpharix suspensie voor injectie in een voorgevulde spuit Trivalent griepvaccin (gefragmenteerd virion, geïnactiveerd)

Alpharix suspensie voor injectie in een voorgevulde spuit Trivalent griepvaccin (gefragmenteerd virion, geïnactiveerd)

Alprazolam

Alteplase

Alunbrig 30 mg film-coated tablets, CRIZOTINIB, LORLATINIB, Zykadia 150 mg hard capsules, ALECTINIB

Alvelestat

Alvelestat (MPH966)

Alxn1920 placebo product, ALXN1920

Amcenestrant

Ametinib combined with bevacizumab

Amifampridine Phosphate

Amifampridine Phosphate 10 MG Oral Tablet

Amikacin (BAY41-6551)

Amikacin inhalation solution (BAY41-6551)

Amiloride

Amimox 500 mg filmdragerade tabletter, Kåvepenin 800 mg filmdragerade tabletter

Amlitelimab, Amlitelimab matching placebo comprised of the same excipients as the Test product without the active substance

Amlitelimab, Amlitelimab matching placebo to test product

Amlitelimab, Amlitelimab matching placebo to test product

Amlitelimab, Placebo

Amondys 45

Amphotericin B

Amyvid 1900 MBq/mL solution for injection, Neuraceq 300 MBq/mL solution for injection, 0.9% (w/v) sodium chloride (Normal Saline), VIZAMYL 400 MBq/mL solution for injection, Amyvid 800 MBq/mL solution for injection

Amyvid 800 MBq/mL solution for injection, ACU193 matching Placebo, Neuraceq 300 MBq/mL solution for injection, ACU193, VIZAMYL 400 MBq/mL solution for injection

An Adaptive Dose Escalation and Expansion Basket Trial to Explore the Safety, Pharmacology, and Clinical Activity of TGD001 in Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP) and Other Thrombotic Microangiopathies

An Open-Label, Multi-Center, Phase Ib/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin (Plus A Single Pretreatment Dose of Obinutuzumab) in Adult Patients with Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma

An Open-label, Phase I/II First-in-Human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumor Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants with Advanced Solid Tumors

An Open-label, Single-arm, Multicenter Pilot Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Pegcetacoplan in Patients with Transplant-associated Thrombotic Microangiopathy (TA-TMA) After Hematopoietic Stem Cell Transplantation (HSCT)

An open label extension study to evaluate the long-term safety and efficacy of subcutaneous lunsekimig in adult participants with asthma who participated in study DRI16762 or ACT18301

An open-label, dose-escalation, dose-finding, and proof-of-concept trial of SP-420 in subjects with transfusion-dependent α- or β-thalassemia or low-risk myelodysplastic syndromes

An open-label, single-arm extension study to evaluate the long-term safety, tolerability, and efficacy of KL1333 (napazimone) in patients with primary mitochondrial disease

Analogs, Prostaglandin E1

Andecaliximab

Angiotensin (1-7)

Anlotinib

Anlotinib Hydrochloride

Anlotinib and Sintilimab injection

Anlotinib combined Docetaxel

Anlotinib plus Pemetrexed

Anlotinib+ Liposomal Doxorubicin

Anrotinib plus Tirelizumab

Anterior lamellar nanostructured artificial human cornea.

Frequently asked questions

Stay Ahead in Pharma